E
Eugene Braunwald
Researcher at Brigham and Women's Hospital
Publications - 1758
Citations - 278949
Eugene Braunwald is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Myocardial infarction & TIMI. The author has an hindex of 230, co-authored 1711 publications receiving 264576 citations. Previous affiliations of Eugene Braunwald include Boston University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis.
Michelle L. O'Donoghue,William E. Boden,Eugene Braunwald,Christopher P. Cannon,Tim Clayton,Robbert J. de Winter,Keith A.A. Fox,Bo Lagerqvist,Peter A. McCullough,Sabina A. Murphy,Rudolf Spacek,Eva Swahn,Lars Wallentin,Fons Windhausen,Marc S. Sabatine +14 more
TL;DR: In NSTE ACS, an invasive strategy has a comparable benefit in men and high-risk women for reducing the composite end point of death, MI, or rehospitalization with ACS, and evidence supporting the new guideline recommendation for a conservative strategy in low- risk women is provided.
Journal ArticleDOI
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the cholesterol and recurrent events (CARE) trial
Sandra J. Lewis,Lemuel A. Moyé,Frank M. Sacks,David E. Johnstone,Gerald C. Timmis,Jayne Mitchell,Marian C. Limacher,Sherron Kell,Stephen P. Glasser,Jane Grant,Barry R. Davis,Marc A. Pfeffer,Eugene Braunwald +12 more
TL;DR: The Cholesterol and Recurrent Events (CARE) trial investigated whether reducing average cholesterol levels by using pravastatin in patients who have had myocardial infarction would prevent recurrent cardiac events, and reported that patients who were older than the median age of 59 years had a reduced rate of coronary death, nonfatal myocardIAL infarctions, coronary artery bypass grafting, angioplasty, and stroke.
Journal ArticleDOI
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
Christian T. Ruff,Robert P. Giugliano,Elliott M. Antman,Sharon Crugnale,Tomas S. Bocanegra,Michele Mercuri,James J. Hanyok,Indravadan Patel,Minggao Shi,Dan Salazar,Carolyn H. McCabe,Eugene Braunwald +11 more
TL;DR: In this paper, a phase 3 comparison of the novel oral factor Xa inhibitor edoxaban to warfarin for the prevention of thromboembolism in patients with atrial fibrillation was conducted.
Journal ArticleDOI
Effects of gender and race on prognosis after myocardial infarction: adverse prognosis for women, particularly black women.
Geoffrey H. Tofler,Peter Stone,James E. Muller,Stefan N. Willich,Vicki G. Davis,W. Kenneth Poole,H. William Strauss,James T. Willerson,Allan S. Jaffe,Thomas S. Robertson,Eugene R. Passamani,Eugene Braunwald +11 more
TL;DR: Findings in the MILIS population indicate that the prognosis after myocardial infarction is worse for women, particularly black women.
Journal ArticleDOI
Nifedipine therapy for coronary-artery spasm. Experience in 127 patients
Elliott M. Antman,James E. Muller,Sheldon Goldberg,Rex N. MacAlpin,Melvyn Rubenfire,Bernard Tabatznik,Chang seng Liang,Fred Heupler,Stephen C. Achuff,Nathaniel Reicher,Edward Geltman,Nicholas Z. Kerin,Raymond K. Neff,Eugene Braunwald +13 more
TL;DR: Clinical experience with nifedipine suggests that it is a highly effective drug for the treatment of coronary-artery spasm and variant angina.